Vyome Holdings, Inc. (HIND)
NASDAQ: HIND · Real-Time Price · USD
5.01
-0.08 (-1.57%)
At close: Dec 5, 2025, 4:00 PM EST
5.08
+0.07 (1.40%)
After-hours: Dec 5, 2025, 7:59 PM EST
Company Description
Vyome Holdings Inc., a clinical-stage healthcare company, develops therapeutic products targeting immuno-inflammatory and rare diseases in the United States and global markets.
The company was founded in 2017 and is based in Cambridge, Massachusetts.
Vyome Holdings, Inc.
| Country | United States |
| Founded | 2017 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 18 |
| CEO | Venkateswarlu Nelabhotla |
Contact Details
Address: Harvard Square, One Mifflin Place Cambridge, Massachusetts 02138 United States | |
| Phone | 973-832-8147 |
| Website | vyometx.com |
Stock Details
| Ticker Symbol | HIND |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001371217 |
| CUSIP Number | 92943X104 |
| ISIN Number | US92943X1046 |
| Employer ID | 48-1293684 |
| SIC Code | 3845 |
Key Executives
| Name | Position |
|---|---|
| Venkateswarlu Nelabhotla M.B.A. | Co-Founder, Chief Executive Officer, President and Director |
| Dr. Shiladitya Sengupta M.Sc., Ph.D. | Co-Founder, Director and Member of Scientific and Clinical Advisory Board |
| Robert Dickey IV | Chief Financial Officer |
| Dr. Richard Fahrner Ph.D. | Chief Technology Officer |
| Dr. Charles G. Chavdarian Ph.D. | Senior Vice President of Product Development and Regulatory CMC |
| Dr. Tamara Agajanov M.D. | Senior Vice President of Clinical Development |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jun 25, 2021 | EFFECT | Notice of Effectiveness |
| Jun 25, 2021 | EFFECT | Notice of Effectiveness |
| Jun 25, 2021 | EFFECT | Notice of Effectiveness |
| Jun 25, 2021 | EFFECT | Notice of Effectiveness |
| Jun 25, 2021 | EFFECT | Notice of Effectiveness |
| Jun 25, 2021 | EFFECT | Notice of Effectiveness |
| Jun 25, 2021 | EFFECT | Notice of Effectiveness |
| Jun 25, 2021 | EFFECT | Notice of Effectiveness |
| Jun 25, 2021 | EFFECT | Notice of Effectiveness |
| Jun 25, 2021 | EFFECT | Notice of Effectiveness |